- Home
- PROK vs PFO Comparison
PROK vs PFO Comparison
Compare PROK & PFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- PFO
- Stock Information
- Founded
- PROK 2015
- PFO 1991
- Country
- PROK United States
- PFO United States
- Employees
- PROK N/A
- PFO N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- PFO Finance Companies
- Sector
- PROK Health Care
- PFO Finance
- Exchange
- PROK Nasdaq
- PFO Nasdaq
- Market Cap
- PROK 126.8M
- PFO 120.4M
- IPO Year
- PROK N/A
- PFO N/A
- Fundamental
- Price
- PROK $1.02
- PFO $8.79
- Analyst Decision
- PROK Buy
- PFO
- Analyst Count
- PROK 4
- PFO 0
- Target Price
- PROK $5.00
- PFO N/A
- AVG Volume (30 Days)
- PROK 1.3M
- PFO 31.8K
- Earning Date
- PROK 05-09-2025
- PFO 01-01-0001
- Dividend Yield
- PROK N/A
- PFO 6.51%
- EPS Growth
- PROK N/A
- PFO N/A
- EPS
- PROK N/A
- PFO N/A
- Revenue
- PROK $76,000.00
- PFO N/A
- Revenue This Year
- PROK N/A
- PFO N/A
- Revenue Next Year
- PROK N/A
- PFO N/A
- P/E Ratio
- PROK N/A
- PFO N/A
- Revenue Growth
- PROK N/A
- PFO N/A
- 52 Week Low
- PROK $0.46
- PFO $6.90
- 52 Week High
- PROK $4.44
- PFO $8.51
- Technical
- Relative Strength Index (RSI)
- PROK 60.91
- PFO 48.20
- Support Level
- PROK $0.66
- PFO $8.50
- Resistance Level
- PROK $0.89
- PFO $8.75
- Average True Range (ATR)
- PROK 0.17
- PFO 0.21
- MACD
- PROK 0.06
- PFO 0.03
- Stochastic Oscillator
- PROK 77.78
- PFO 79.10
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.